{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T08:06:46Z","timestamp":1772611606587,"version":"3.50.1"},"reference-count":137,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Radioligand therapy (RLT) offers the ability to deliver radiation to specific cells based on the presence of certain targets. RLT with [177Lu]Lu-DOTATATE was approved in 2018 by the US Food and Drug Administration (FDA) for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). As RLT has become integrated into clinical practice, understanding the presence of and management strategies associated with acute, subacute, or delayed toxicities is essential to optimize patient outcomes. In this review article, we consider the risk factors for complications and any preventative strategies that may be employed. We present an overview of the toxicities that could occur during or soon after RLT infusion and discuss recommended management strategies, both from the literature and from experience in the clinical administration of RLT for patients with GEP-NETs. We highlight the importance of robust procedures for handling emergency situations and the potential for radioactive contamination from patients\u2019 bodily fluids. Furthermore, the potential for delayed toxicities is also considered. In addition to toxicities and management, we also review the practical radiation safety precautions that are important both during and following RLT treatment.<\/jats:p>","DOI":"10.3390\/cancers18050742","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:58:03Z","timestamp":1772114283000},"page":"742","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Occurrence and Management of Acute, Subacute, and Delayed Toxicities in Patients with GEP-NETs Following Treatment with Radioligand Therapy"],"prefix":"10.3390","volume":"18","author":[{"given":"Ghassan","family":"El-Haddad","sequence":"first","affiliation":[{"name":"Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6338-3833","authenticated-orcid":false,"given":"Linda","family":"Gardner","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Theranostics, UCLA Health, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4029-8764","authenticated-orcid":false,"given":"Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Washington University, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-2583","authenticated-orcid":false,"given":"Heloisa P.","family":"Soares","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84132, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1007\/s00259-023-06217-0","article-title":"Radioligand therapies in cancer: Mapping the educational landscape in Europe","volume":"50","author":"Bugani","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: Clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Liang, Q., Li, X., Cai, H., Song, W., Lan, X., Veronesi, M.C., and Cai, W. (2025). Radiopharmaceutical therapy: From bench to bedside. Acta Pharm. Sin. B, in press.","DOI":"10.1016\/j.apsb.2025.12.009"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sachpekidis, C., Jackson, D.B., and Soldatos, T.G. (2019). Radioimmunotherapy in Non-Hodgkin\u2019s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar. Pharmaceuticals, 12.","DOI":"10.3390\/ph12040141"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nbt1218-1125","article-title":"Radioactive drugs emerge from the shadows to storm the market","volume":"36","author":"Dolgin","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40291-024-00702-4","article-title":"Advances in Radioligand Theranostics in Oncology","volume":"28","author":"Lawal","year":"2024","journal-title":"Mol. Diagn. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Merola, E., and Grana, C.M. (2023). Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements. Cancers, 15.","DOI":"10.3390\/cancers15112975"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Puliani, G., Chiefari, A., Mormando, M., Bianchini, M., Lauretta, R., and Appetecchia, M. (2022). New Insights in PRRT: Lessons From 2021. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.861434"},{"key":"ref_10","unstructured":"(2026, January 27). Future Market Insights. Peptide Receptor Radionuclide Therapy (PRRT) Market. Peptide Receptor Radionuclide Therapy (PRRT) Market Trends and Forecast 2025 to 2035. Available online: https:\/\/www.futuremarketinsights.com\/reports\/peptide-receptor-radionuclide-therapy-prrt-market."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hennrich, U., and Kopka, K. (2019). Lutathera\u00ae: The first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals, 12.","DOI":"10.3390\/ph12030114"},{"key":"ref_12","unstructured":"Novartis Pharmaceuticals Corporation (2025, November 04). Lutathera\u00ae Prescribing Information. Available online: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/lutathera.pdf."},{"key":"ref_13","unstructured":"U.S. Food & Drug Administration (2024). FDA Approves Lutetium Lu 177 Dotatate for Pediatric Patients 12 Years and Older with GEP-NETS."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","article-title":"Nothing But NET: A review of neuroendocrine tumors and carcinomas","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2124750","DOI":"10.1001\/jamanetworkopen.2021.24750","article-title":"Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.cgh.2018.12.017","article-title":"Incidence trends of gastroenteropancreatic neuroendocrine tumors in the United States","volume":"17","author":"Lee","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40842-018-0066-3","article-title":"Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)","volume":"4","author":"Uri","year":"2018","journal-title":"Clin. Diabetes Endocrinol."},{"key":"ref_18","unstructured":"National Comprehensive Cancer Network (2025, November 04). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Neuroendocrine and Adrenal Tumors. Version 4.2024\u2013January 2025. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11912-009-0028-0","article-title":"Progress in the treatment of neuroendocrine tumors","volume":"11","author":"Chan","year":"2009","journal-title":"Curr. Oncol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000287277","article-title":"ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors","volume":"91","author":"Pavel","year":"2010","journal-title":"Neuroendocrinology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","article-title":"177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors","volume":"13","author":"Das","year":"2019","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/1097-0215(20010601)92:5<628::AID-IJC1244>3.0.CO;2-L","article-title":"[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy","volume":"92","author":"Breeman","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Maier, P., Hartmann, L., Wenz, F., and Herskind, C. (2016). Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010102"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chauhan, A., Del Rivero, J., Ramirez, R.A., Soares, H.P., and Li, D. (2022). Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review. Cancers, 14.","DOI":"10.3390\/cancers14215248"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): An open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_30","unstructured":"Capdevila, J.A., Amthauer, H., Ansquer, C., Deshayes, E., Garcia-Carbonero, R., Teul\u00e9-Vega, A., Wilmink, J., Cwikla, J.B., Srirajaskanthan, R., and Buck, A. (2025, January 5\u20137). Efficacy and safety of [177Lu]Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE Phase 3 trial. Proceedings of the European Neuroendocrine Tumor Society (ENETS), Krak\u00f3w, Poland."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s00259-025-07418-5","article-title":"Complications and outcomes of radioligand therapy in patients with neuroendocrine neoplasms depending on the baseline glomerular filtration rate","volume":"53","author":"Durma","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Durma, A.D., Saracyn, M., Ko\u0142odziej, M., J\u00f3\u017awik-Plebanek, K., Brodowska-Kania, D., Dmochowska, B., Mr\u00f3z, A., Kos-Kud\u0142a, B., and Kami\u0144ski, G. (2024). Adverse Events of Radioligand Therapy in Patients with Progressive Neuroendocrine Neoplasms: The Biggest Eastern European Prospective Study. Cancers, 16.","DOI":"10.3390\/cancers16203509"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Saracyn, M., Durma, A.D., Bober, B., Lubas, A., Ko\u0142odziej, M., Kapusta, W., Dmochowska, B., and Kami\u0144ski, G. (2023). Renal Disturbances During and After Radioligand Therapy of Neuroendocrine Tumors-Extended Analysis of Potential Acute and Chronic Complications. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087508"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1097\/RLU.0000000000004642","article-title":"Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE With and Without Amino Acid Infusion","volume":"48","author":"Jiang","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2967\/jnumed.118.230607","article-title":"NANETS\/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE","volume":"60","author":"Hope","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ladri\u00e8re, T., Faudemer, J., Levigoureux, E., Peyronnet, D., Desmonts, C., and Vigne, J. (2023). Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041240"},{"key":"ref_37","unstructured":"Novartis Pharmaceuticals Corporation (2026, January 27). Lutathera\u00ae Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lutathera-epar-product-information_en.pdf."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2967\/jnmt.122.263813","article-title":"Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs","volume":"50","author":"Soulek","year":"2022","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2214\/AJR.19.21123","article-title":"Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients with Neuroendocrine Tumors","volume":"213","author":"Kendi","year":"2019","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/MPA.0000000000001795","article-title":"Comparison of nausea and vomiting associated with amino acid formulations coinfused with peptide receptor radionuclide therapy: Commercial parenteral nutrition formulas versus compounded arginine\/lysine","volume":"50","author":"Sikaria","year":"2021","journal-title":"Pancreas"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2214\/AJR.20.23349","article-title":"Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice","volume":"217","author":"Sheikhbahaei","year":"2021","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2214\/AJR.22.28237","article-title":"Integrating Theranostics into Patient Care Pathways: AJR Expert Panel Narrative Review","volume":"220","author":"Iravani","year":"2023","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Del Olmo-Garc\u00eda, M.I., Muros, M.A., L\u00f3pez-de-la-Torre, M., Agudelo, M., Bello, P., Soriano, J.M., and Merino-Torres, J.F. (2020). Prevention and Management of Hormonal Crisis During Theragnosis with LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072203"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000461583","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors","volume":"105","author":"Kaltsas","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Bardasi, C., Benatti, S., Luppi, G., Garajov\u00e0, I., Piacentini, F., Dominici, M., and Gelsomino, F. (2022). Carcinoid Crisis: A Misunderstood and Unrecognized Oncological Emergency. Cancers, 14.","DOI":"10.3390\/cancers14030662"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100623","DOI":"10.1016\/j.adro.2020.11.008","article-title":"Lutetium Lu-177 Dotatate Flare Reaction","volume":"6","author":"Salner","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.13403","article-title":"Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology","volume":"169","author":"Jones","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1756-8722-5-75","article-title":"Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies","volume":"5","author":"McBride","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anai.2023.09.015","article-title":"Anaphylaxis: A 2023 practice parameter update","volume":"132","author":"Golden","year":"2024","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2967\/jnumed.123.265706","article-title":"Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients","volume":"65","author":"Strosberg","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Sukrithan, V., Armbruster, H., Rogers, S., Vogt, S.M., Grenade, C., Verschraegen, C., Zhou, Y., Goyal, A., Natwa, M., and Hussein, A. (2024). Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience. PLoS One, 19.","DOI":"10.1371\/journal.pone.0298824"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"517","DOI":"10.51821\/87.4.13105","article-title":"Successful reversal of intestinal obstruction by PRRT: Two case reports and literature review of PRRT in Small Intestinal Neuroendocrine Tumors with mesenteric fibrosis","volume":"87","author":"Dubois","year":"2024","journal-title":"Acta Gastro Enterol. Belg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2967\/jnumed.123.266063","article-title":"Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network","volume":"65","author":"Haissaguerre","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2967\/jnumed.120.242875","article-title":"Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy","volume":"62","author":"Strosberg","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_55","unstructured":"Vercruysse, G., Busch, R., Dimcheff, D., Al-Hawary, M., Saad, R., Seagull, J., Somand, D., Cherry-Bukowiec, J., Wanacata, L., and Pumiglia, L. (2025, November 04). Evaluation and Management of Mechanical Small Bowel Obstruction in Adults, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572336\/."},{"key":"ref_56","first-page":"20","article-title":"A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report","volume":"14","author":"Amthauer","year":"2021","journal-title":"Mol. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Sabet, A., Mader, N., Bittenbring, J.T., Khreish, F., Gr\u00fcnwald, F., Biersack, H.J., and Ezziddin, S. (2021). Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Pharmaceuticals, 14.","DOI":"10.3390\/ph14101022"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1634\/theoncologist.2011-S3-12","article-title":"Management of anemia in cancer patients: Transfusions","volume":"16","author":"Schrijvers","year":"2011","journal-title":"Oncologist"},{"key":"ref_59","first-page":"825","article-title":"Management of neutropenia in cancer patients","volume":"10","author":"Lustberg","year":"2012","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Osborne, D.R. (2023). Radiopharmaceutical extravasations: A twenty year mini-review. Front. Nucl. Med., 3.","DOI":"10.3389\/fnume.2023.1219202"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/ejhpharm-2019-002152","article-title":"An update on extravasation: Basic knowledge for clinical pharmacists","volume":"28","author":"Smolders","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1007\/s00259-017-3675-7","article-title":"Consequences of radiopharmaceutical extravasation and therapeutic interventions: A systematic review","volume":"44","author":"Bucerius","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_63","unstructured":"US Nuclear Regulatory Commission (2025, November 04). Rulemaking: Reporting Nuclear Medicine Injection Extravasations as Medical Events, Available online: https:\/\/www.nrc.gov\/materials\/miau\/med-use-toolkit\/reporting-nuclear-medicine-injection-extravasations.html."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5603\/NMR.a2022.0030","article-title":"Amino acid extravasation: A rare red flag to keep in mind during peptide receptor radioligand therapy (PRRT) with [177Lu]Lu-DOTATATE","volume":"25","author":"Divband","year":"2022","journal-title":"Nucl. Med. Rev. Cent. East. Eur."},{"key":"ref_65","unstructured":"American College of Radiology (2025, November 04). ACR Manual on Contrast Media. Available online: https:\/\/www.acr.org\/Clinical-Resources\/Clinical-Tools-and-Reference\/Contrast-Manual."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/archsurg.1979.01370320029005","article-title":"Factors determining peripheral vein tolerance to amino acid infusions","volume":"114","author":"Gazitua","year":"1979","journal-title":"Arch. Surg."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13550-020-00658-6","article-title":"Extravasation of [177Lu]Lu-DOTATOC: Case report and discussion","volume":"10","author":"Arveschoug","year":"2020","journal-title":"EJNMMI Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2021.06.006","article-title":"Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours","volume":"102\u2013103","author":"Geenen","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"20180108","DOI":"10.1259\/bjr.20180108","article-title":"Theranostics in neuroendocrine tumours: Somatostatin receptor imaging and therapy","volume":"91","author":"Pencharz","year":"2018","journal-title":"Br. J. Radiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/1874471015666211228123525","article-title":"Comparison of Two Types of Amino Acid Solutions on 177Lu-Dotatate Pharmacokinetics and Pharmacodynamics in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors","volume":"15","author":"Lambert","year":"2022","journal-title":"Curr. Radiopharm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00259-007-0691-z","article-title":"Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate","volume":"35","author":"Feelders","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Bongiovanni, A., Nicolini, S., Ibrahim, T., Foca, F., Sansovini, M., Di Paolo, A., Grassi, I., Liverani, C., Calabrese, C., and Ranallo, N. (2022). 177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials. Cancers, 14.","DOI":"10.3390\/cancers14246022"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s41824-024-00216-6","article-title":"Carcinoid crisis in Lutetium-177-Dotatate therapy of neuroendocrine tumors: An overview of pathophysiology, risk factors, recognition, and treatment","volume":"8","author":"Sozio","year":"2024","journal-title":"EJNMMI Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jcrc.2020.08.011","article-title":"Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report","volume":"60","author":"Dhanani","year":"2020","journal-title":"J. Crit. Care"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2967\/jnumed.118.217380","article-title":"Tumor Lysis Syndrome: A Rare but Serious Complication of Radioligand Therapies","volume":"60","author":"Huang","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2165\/00002018-199308040-00003","article-title":"Adverse reactions and drug interactions with radiopharmaceuticals","volume":"8","author":"Sampson","year":"1993","journal-title":"Drug Saf."},{"key":"ref_77","first-page":"142","article-title":"Adverse reactions to radiopharmaceuticals","volume":"45","year":"2021","journal-title":"Farm. Hosp."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.prro.2024.07.002","article-title":"Unplanned Emergency Department or Inpatient Acute Care Within 1 Week After Administration of Peptide Receptor Radionuclide Therapy: Frequency of Occurrence and Standard Operating Procedures for Radioprotection in These Situations","volume":"15","author":"Prabhu","year":"2024","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.prro.2023.12.014","article-title":"Handling Patient Emergencies During Radiopharmaceutical Therapy","volume":"14","author":"Maughan","year":"2024","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EJE-14-0488","article-title":"GEPNETs update: Radionuclide therapy in neuroendocrine tumors","volume":"172","author":"Bodei","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","article-title":"Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: Prognostic factors, incidence and course","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"de Vries-Huizing, D.M.V., Versleijen, M.W.J., Sinaasappel, M., Walraven, I., Geluk-Jonker, M.M., Tesselaar, M.E.T., Hendrikx, J., de Wit-van der Veen, B.J., and Stokkel, M.P.M. (2021). Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient\u2019s therapy course. PLoS One, 16.","DOI":"10.1371\/journal.pone.0260073"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1200\/JCO.2024.42.16_suppl.4131","article-title":"Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study","volume":"42","author":"Kunz","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.112.119347","article-title":"Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"54","author":"Sabet","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_85","first-page":"381","article-title":"Short-Term Biological Toxicity Prediction of [177Lu]Lutetium-Oxodotreotide: An Original Retrospective Analysis","volume":"39","author":"Dubois","year":"2024","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/RLU.0000000000004130","article-title":"Severe Thrombocytopenia in Patients with Advanced Neuroendocrine Tumor Treated with Peptide Receptor Radioligand Therapy","volume":"47","author":"Schroeder","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"ref_87","first-page":"Cd010756","article-title":"Corticosteroids for the management of cancer-related pain in adults","volume":"2015","author":"Haywood","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Pelle, E., Al-Toubah, T., El-Haddad, G., and Strosberg, J. (2023, January 4\u20136). Small bowel ischemia in patients with midgut neuroendocrine tumors after treatment with 177Lutetium-Dotatate. Proceedings of the 2023 North American Neuroendocrine Tumor Society, Montreal, QC, Canada.","DOI":"10.1530\/endoabs.98.C29"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/1078155210384445","article-title":"Incidence of myelodysplastic syndromes in patients receiving concurrent myelosuppressive chemotherapy and pegfilgrastim","volume":"17","author":"Covert","year":"2011","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: The value and limitations of clinical factors","volume":"42","author":"Bodei","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2967\/jnumed.117.189712","article-title":"Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors","volume":"59","author":"Bergsma","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00259-018-4158-1","article-title":"Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours","volume":"46","author":"Brabander","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"102141","DOI":"10.1016\/j.ctrv.2020.102141","article-title":"Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis","volume":"93","author":"Strosberg","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"L17","DOI":"10.1530\/ERC-15-0543","article-title":"High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy","volume":"23","author":"Brieau","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1530\/ERC-16-0258","article-title":"Myeloid neoplasms after chemotherapy and PRRT: Myth and reality","volume":"23","author":"Bodei","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2022.40.4_suppl.513","article-title":"Risk of myelodysplastic syndrome\/acute leukemia with sequential capecitabine\/temozolomide and 177Lu-dotatate","volume":"40","author":"Pelle","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Halfdanarson, T.R., Mallak, N., Paulson, S., Chandrasekharan, C., Natwa, M., Kendi, A.T., and Kennecke, H.F. (2023). Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy. Cancers, 15.","DOI":"10.3390\/cancers15194836"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e250025","DOI":"10.1530\/ERC-25-0025","article-title":"Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: How great is the risk?","volume":"32","author":"Kusne","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1053\/j.semnuclmed.2022.02.004","article-title":"The Impact of Radiopharmaceutical Therapy on Renal Function","volume":"52","author":"Park","year":"2022","journal-title":"Semin. Nucl. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"101295","DOI":"10.1016\/j.tranon.2021.101295","article-title":"Nephrotoxicity after radionuclide therapies","volume":"15","author":"Parihar","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA(0),Tyr(3)]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","article-title":"Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2967\/jnumed.123.265986","article-title":"Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy","volume":"65","author":"Steinhelfer","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00259-023-06559-9","article-title":"Pre-clinical Evaluation of Biomarkers for Early Detection of Nephrotoxicity Following Alpha-Particle Radioligand Therapy","volume":"51","author":"Li","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"451","DOI":"10.7150\/thno.92487","article-title":"Long-Term Nephrotoxicity After PRRT: Myth or Reality","volume":"14","author":"Baum","year":"2024","journal-title":"Theranostics"},{"key":"ref_106","first-page":"83S","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and 177Lu-DOTA(0), Tyr(3)-octreotate","volume":"46","author":"Valkema","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/ndt\/gfw338","article-title":"Nephrotoxicity of anticancer treatment","volume":"32","author":"Malyszko","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","article-title":"Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: An analysis of the NETTER-1 study","volume":"47","author":"Strosberg","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2967\/jnumed.122.264533","article-title":"Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden","volume":"64","author":"Kuhlman","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/oncolo\/oyab072","article-title":"Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up","volume":"27","author":"Duan","year":"2022","journal-title":"Oncologist"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1530\/ERC-16-0524","article-title":"Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate","volume":"24","author":"Brabander","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/RLU.0000000000000935","article-title":"Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients with Metastatic Neuroendocrine Tumors","volume":"40","author":"Riff","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Ramdhani, K., and Braat, A. (2022). The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases. Cancers, 14.","DOI":"10.3390\/cancers14143415"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1055\/s-0040-1720951","article-title":"Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases in the Era of Peptide Receptor Radionuclide Therapy","volume":"37","author":"Lehrman","year":"2020","journal-title":"Semin. Interv. Radiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3390\/gastroent15040065","article-title":"Non-Cirrhotic Ascites: Causes and Management","volume":"15","author":"Carrier","year":"2024","journal-title":"Gastroenterol. Insights"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2967\/jnmt.121.262820","article-title":"Risk of Radiation Exposure to Clinical Staff from Paracenteses of Large-Volume Chylous Ascites After 177Lu-DOTATATE Infusion","volume":"50","author":"Tipnis","year":"2022","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep.24786","article-title":"Albumin infusion in patients undergoing large-volume paracentesis: A meta-analysis of randomized trials","volume":"55","author":"Bernardi","year":"2012","journal-title":"Hepatology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1200\/JCO.2024.42.4_suppl.99","article-title":"Preliminary reliability of the FACT-RNT in standard-of-care Lu-PSMA therapy of metastatic castration-resistant prostate cancer","volume":"42","author":"Gudenkauf","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2025.43.5_suppl.118","article-title":"Implementation and preliminary validity of the Functional Assessment of Cancer Therapy\u2014Radionuclide Therapy (FACT-RNT) in patients receiving radionuclide therapy for prostate cancer","volume":"43","author":"Gudenkauf","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Ninatti, G., Lee, S.T., and Scott, A.M. (2025). Radioligand Therapy in Cancer Management: A Global Perspective. Cancers, 17.","DOI":"10.3390\/cancers17213412"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1874471014666210810100435","article-title":"Toxicity and Tolerability of 177Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin\u2014A Phase 2 Registry Study","volume":"15","author":"Khatami","year":"2022","journal-title":"Curr. Radiopharm."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1007\/s00259-022-05786-w","article-title":"Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients","volume":"49","author":"Gleisner","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2967\/jnumed.124.269378","article-title":"Rethinking Dosimetry: A European Perspective","volume":"66","author":"Cicone","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00259-020-04745-7","article-title":"Realising the potential of radioligand therapy: Policy solutions for the barriers to implementation across Europe","volume":"47","author":"Merkel","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Aouf, A., Speicher, T., Blickle, A., Bastian, M.B., Burgard, C., Rosar, F., Ezziddin, S., and Sabet, A. (2025). Prediction of lesion-based response to PRRT using baseline somatostatin receptor PET. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1523862"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2967\/jnumed.122.264363","article-title":"Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumors","volume":"64","author":"Bodei","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Azadinejad, H., Farhadi Rad, M., Shariftabrizi, A., Rahmim, A., and Abdollahi, H. (2025). Optimizing Cancer Treatment: Exploring the Role of AI in Radioimmunotherapy. Diagnostics, 15.","DOI":"10.3390\/diagnostics15030397"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40001-023-01627-0","article-title":"Radiopharmaceuticals: Navigating the frontier of precision medicine and therapeutic innovation","volume":"29","author":"Dhoundiyal","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e13393","DOI":"10.1111\/jne.13393","article-title":"Use of approved Lu-177 radiopharmaceuticals in patients with end-stage renal disease: A review of the literature and proposed treatment algorithm","volume":"36","author":"Trikalinos","year":"2024","journal-title":"J. Neuroendocrinol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40336-025-00679-y","article-title":"Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) practical guide for peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-Oxodotreotide in gastroenteropancreatic neuroendocrine tumors (GEP-NET)","volume":"13","author":"Laudicella","year":"2025","journal-title":"Clin. Transl. Imaging"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Zamponi, V., La Salvia, A., Tarsitano, M.G., Mikovic, N., Rinzivillo, M., Panzuto, F., Giannetta, E., Faggiano, A., and Mazzilli, R. (2022). Effect of Neuroendocrine Neoplasm Treatment on Human Reproductive Health and Sexual Function. J. Clin. Med., 11.","DOI":"10.3390\/jcm11143983"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MPA.0000000000002002","article-title":"Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy","volume":"51","author":"Hendifar","year":"2022","journal-title":"Pancreas"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40658-019-0243-1","article-title":"Radiation precautions for inpatient and outpatient (177)Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours","volume":"6","author":"Levart","year":"2019","journal-title":"EJNMMI Phys."},{"key":"ref_135","unstructured":"LACNETS.org (2026, February 09). The LACNETS Podcast. Episode 8. PRRT (Part I). Available online: https:\/\/www.ncf.net\/podcast\/8."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2967\/jnumed.120.243238","article-title":"Patient Travel Concerns After Treatment with (177)Lu-DOTATATE","volume":"61","author":"Kendi","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/HP.0000000000001644","article-title":"Clinical Best Practices for Radiation Safety During Lutetium-177 Therapy","volume":"124","author":"Cappon","year":"2023","journal-title":"Health Phys."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/742\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:15:01Z","timestamp":1772601301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":137,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18050742"],"URL":"https:\/\/doi.org\/10.3390\/cancers18050742","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]}}}